Floatz logo

Gusacitinib

Systemic Lupus Erythematosus

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Systemic Lupus Erythematosus cohort.

Asset / SponsorPhaseRating
Prasterone
National Center for Research Resources (NCRR)
Phase 3BB
WARFARIN
University College, London
Phase 2B
Rivaroxaban
University College, London
Phase 2B
TECHNETATE(3-)-99TC, (N-(4-(((2-AMINO-1,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-D-.GAMMA.-GLUTAMYL-(2S)-2-(AMINO-.KAPPA.N)-.BETA.-ALANYL-L-.ALPHA.-ASPARTYL-.KAPPA.N-L-CYSTEINATO(6-)-.KAPPA.N,.KAPPA.S)OXO-, HYDROGEN (1:3), (SP-5-24)-
Mayo Clinic
Phase 2B
Cytosin-Arabinosid
National Center for Research Resources (NCRR)
Phase 2B

View all 34 →

Same molecule, other indications

Gusacitinib is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
48 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
primary myelofibrosisDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →